低危主动脉瓣狭窄患者经导管与外科主动脉瓣置换术后健康状态比较
PARTNER 3试验随机分配1000例低危重度主动脉瓣狭窄患者接受经股动脉球囊扩张瓣膜TAVR或外科换瓣,用KCCQ、SF-36和EQ-5D评估健康状态。TAVR组1个月时KCCQ-OS评分改善显著优于外科组,6个月和12个月优势减小但仍存在;6个月时TAVR组达到优良结局的比例更高。
要点
- 低危重度AS患者TAVR术后1个月健康状态改善明显优于外科换瓣。
- TAVR的健康状态优势持续至12个月,但6个月后效应量减小。
- 6个月时TAVR组优良结局比例更高,12个月时差异未达统计学显著。
核心结论
- 在低危重度AS患者中,TAVR相比外科换瓣与早期和晚期有意义的健康状态获益相关。
研究设计与样本
- PARTNER 3试验于2016年3月至2017年10月随机分配1000例低危AS患者接受经股动脉球囊扩张瓣膜TAVR或外科换瓣。
- 健康状态在基线及1、6、12个月用KCCQ、SF-36和EQ-5D评估,主要终点为KCCQ-OS评分随时间变化,采用纵向增长曲线模型比较组间差异。
主要发现
- 1个月时TAVR组KCCQ-OS平均差异为16.0分(p < 0.001),优于外科组。
- 6个月和12个月时TAVR组KCCQ-OS平均差异分别为2.6分和1.8分(两者p < 0.04),健康状态仍更优但效应减小。
- 达到优良结局(存活且KCCQ-OS ≥75且较基线无显著下降)的比例,TAVR组6个月为90.3% vs 外科组85.3%(p = 0.03),12个月为87.3% vs 82.8%(p = 0.07)。
临床怎么用
- 对于低危重度AS患者,选择TAVR时除考虑死亡、卒中和再住院外,还应关注早期健康状态改善的优势。
- TAVR的健康状态获益在术后早期最显著,6个月后优势减小,需结合患者预期和偏好进行共同决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with severe aortic stenosis (AS) at low surgical risk, treatment with transcatheter aortic valve replacement (TAVR) results in lower rates of death, stroke, and rehospitalization at 1 year compared with surgical aortic valve replacement; however, the effect of treatment strategy on health status is unknown. OBJECTIVES: This study sought to compare health status outcomes of TAVR versus surgery in low-risk patients with severe AS. METHODS: Between March 2016 and October 2017, 1,000 low-risk patients with AS were randomized to transfemoral TAVR using a balloon-expandable valve or surgery in the PARTNER 3 (Placement of Aortic Transcatheter Valves) trial. Health status was assessed at baseline and 1, 6, and 12 months using the KCCQ (Kansas City Cardiomyopathy Questionnaire), SF-36 (Short Form-36 Health Survey), and EQ-5D (EuroQoL). The primary endpoint was change in KCCQ-OS (KCCQ Overall Summary) score over time. Longitudinal growth curve modeling was used to compare changes in health status between treatment groups over time. RESULTS: At 1 month, TAVR was associated with better health status than surgery (mean difference in KCCQ-OS 16.0 points; p < 0.001). At 6 and 12 months, health status remained better with TAVR, although the effect was reduced (mean difference in KCCQ-OS 2.6 and 1.8 points respectively; p < 0.04 for both). The proportion of patients with an excellent outcome (alive with KCCQ-OS ≥75 and no significant decline from baseline) was greater with TAVR than surgery at 6 months (90.3% vs. 85.3%; p = 0.03) and 12 months (87.3% vs. 82.8%; p = 0.07). CONCLUSIONS: Among low-risk patients with severe AS, TAVR was associated with meaningful early and late health status benefits compared with surgery.
引用
- Baron SJ, Magnuson EA, Lu M, et al. Health Status After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. J Am Coll Cardiol. 2019. PMID: 31577923. doi:10.1016/j.jacc.2019.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。